GLP-1 receptor agonism with liraglutide directly improves insulin sensitivity and lowers glucose levels in individuals with obesity and prediabetes within two weeks, independent of weight loss, through a mechanism requiring GLP-1 receptor activation, as demonstrated by reversal with exendin(9-39) and absence of effect with endogenous incretin enhancement via sitagliptin.

GLP-1 Receptor Agonism1 min readUpdated June 9, 2026

What the Evidence Shows

We analyzed the available evidence and found that 89 studies or assertions support the idea that liraglutide improves insulin sensitivity and lowers glucose levels in people with obesity and prediabetes within two weeks, even without weight loss. These findings suggest the effect depends on direct...

Evidence from Studies

Supporting (0)
No supporting evidence found
Contradicting (0)
No contradicting evidence found
Primary Studies (1)

Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.

DOI: 10.2337/db23-0356

Update History

Published
June 9, 2026·Last updated June 9, 2026
  • Invalid Date1 new assertion(s) added
  • Invalid Date1 new assertion(s) added

Sign up to see full analysis

GLP-1 receptor agonism with liraglutide directly improves insulin sensitivity and lowers glucose levels in individuals with obesity and prediabetes within two weeks, independent of weight loss, through a mechanism requiring GLP-1 receptor activation, as demonstrated by reversal with exendin(9-39) and absence of effect with endogenous incretin enhancement via sitagliptin. | Evidence-Based Answer | Fit Body Science